CIK 0002023658 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Bicara Therapeutics Inc.
Sign in to watch- Ticker
- BCAX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-468-4219
- Business address
- 116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $400,716
- in 1 filing, $401K under 10b5-1 plans
Net −$400,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-21 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −9,200 | $20.42 | $188K | 145,355 |
| 2026-05-21 | Hyep Ivan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,200 | 70,584 | ||
| 2026-05-18 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 | +15,000 | $3.79 | $57K | 377,152 |
| 2026-05-18 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 | −12,022 | $19.96 | $240K | 365,130 |
| 2026-05-18 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 | −2,978 | $20.35 | $61K | 362,152 |
| 2026-05-18 | Mazumdar Claire Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,000 | 146,107 | ||
| 2026-05-15 | Cohlhepp Ryan President and COO | Option exercise 10b5-1 | +8,000 | $3.79 | $30K | 204,141 |
| 2026-05-15 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −8,000 | $20.29 | $162K | 196,141 |
| 2026-05-15 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −4,500 | $20.29 | $91K | 191,641 |
| 2026-05-15 | Cohlhepp Ryan President and COO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,000 | 101,334 | ||
| 2026-05-08 | Schelman William Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +85,000 | 85,000 | ||
| 2026-04-27 | Raben David Chief Medical Officer | Option exercise 10b5-1 | +5,500 | $3.79 | $21K | 60,786 |
| 2026-04-27 | Raben David Chief Medical Officer | Sale 10b5-1 | −5,500 | $22.88 | $126K | 55,286 |
| 2026-04-27 | Raben David Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,500 | 41,913 | ||
| 2026-04-21 | Hyep Ivan Chief Financial Officer | Option exercise 10b5-1 | +9,200 | $3.79 | $35K | 154,555 |
| 2026-04-21 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −9,200 | $23.00 | $212K | 145,355 |
| 2026-04-21 | Hyep Ivan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,200 | 39,744 | ||
| 2026-04-20 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 | +15,000 | $3.79 | $57K | 377,152 |
| 2026-04-20 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 | −15,000 | $23.61 | $354K | 362,152 |
| 2026-04-20 | Mazumdar Claire Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,000 | 161,107 |
Page 3 of 14 · 276 trades